Zepbound Beats Wegovy in First Head-to-Head Trial
Eli Lilly's GLP-1 drug Zepbound helped nearly 25 percent more participants lose weight than Novo Nordisk's Wegovy, according to the trial results.

May 23, 2025 0
May 23, 2025 0
May 23, 2025 0
May 23, 2025 0
Or register with email
May 16, 2025 0
May 21, 2025 0
May 22, 2025 0
May 23, 2025 0
May 21, 2025 0